Xilio Therapeutics (NASDAQ:XLO) Given New $13.00 Price Target at Raymond James
Xilio Therapeutics (NASDAQ:XLO) Given New $13.00 Price Target at Raymond James
Xilio Therapeutics (NASDAQ:XLO – Get Rating) had its price target lowered by Raymond James from $31.00 to $13.00 in a research report sent to investors on Thursday morning, Benzinga reports. The firm currently has an outperform rating on the stock.
據Benzinga報道，在週四上午發給投資者的一份研究報告中，雷蒙德·詹姆斯將希利奧治療公司(納斯達克代碼：XLO-GET評級)的目標價從31.00美元下調至13.00美元。該公司目前對該股的評級為跑贏大盤。
Separately, Morgan Stanley dropped their price target on Xilio Therapeutics from $32.00 to $20.00 and set an overweight rating on the stock in a research report on Wednesday, August 10th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Xilio Therapeutics currently has a consensus rating of Buy and a consensus target price of $16.50.
另外，摩根士丹利在8月10日(星期三)的一份研究報告中將喜力治療的目標價從32.00美元下調至20.00美元，並對該股設定了增持評級。根據MarketBeat.com的數據，五位投資分析師對該股的評級為買入，Xilio治療公司目前的共識評級為買入，共識目標價為16.50美元。
Xilio Therapeutics Stock Performance
喜力治療的股票表現
Shares of XLO stock traded up $0.15 on Thursday, hitting $2.44. 12,826 shares of the stock traded hands, compared to its average volume of 25,352. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.17 and a quick ratio of 9.17. The company has a market capitalization of $67.03 million and a PE ratio of -0.72. Xilio Therapeutics has a 1-year low of $2.01 and a 1-year high of $27.95. The company's fifty day moving average is $2.54 and its 200 day moving average is $2.77.
週四，XLO股價上漲0.15美元，觸及2.44美元。該股有12,826股易手，而其平均成交量為25,352股。該公司的債務權益比為0.04，流動比率為9.17，速動比率為9.17。該公司市值為6,703萬美元，市盈率為-0.72。喜力治療的一年低點為2.01美元，一年高位為27.95美元。該公司的50日移動均線切入位在2.54美元，200日移動均線切入位在2.77美元。
Institutional Investors Weigh In On Xilio Therapeutics
機構投資者看好希利奧治療公司
Several large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in Xilio Therapeutics by 47.7% in the first quarter. Bank of New York Mellon Corp now owns 21,029 shares of the company's stock worth $149,000 after buying an additional 6,791 shares during the period. State Street Corp grew its stake in shares of Xilio Therapeutics by 58.5% in the first quarter. State Street Corp now owns 93,861 shares of the company's stock worth $664,000 after purchasing an additional 34,651 shares in the last quarter. Bailard Inc. bought a new position in shares of Xilio Therapeutics in the second quarter worth $107,000. Millennium Management LLC bought a new position in shares of Xilio Therapeutics in the second quarter worth $146,000. Finally, Renaissance Technologies LLC bought a new position in shares of Xilio Therapeutics in the second quarter worth $220,000. 64.66% of the stock is owned by institutional investors and hedge funds.
幾家大型投資者最近增持或減持了該股。紐約梅隆銀行第一季度將其在Xilio Treeutics的頭寸增加了47.7%。紐約梅隆銀行(Bank Of New York Mellon Corp)目前持有21,029股該公司股票，價值149,000美元，在此期間又購買了6,791股。道富集團在第一季度增持了Xilio Treeutics的股份58.5%。道富銀行目前持有93,861股該公司股票，價值664,000美元，此前該公司在上個季度又購買了34,651股。Bailard Inc.在第二季度購買了價值10.7萬美元的希利奧治療公司的新股票頭寸。千禧管理公司在第二季度購買了價值14.6萬美元的西利奧治療公司的新股票頭寸。最後，復興科技有限責任公司在第二季度購買了價值22萬美元的西利奧治療公司的新股票頭寸。64.66%的股票由機構投資者和對衝基金持有。
About Xilio Therapeutics
關於希利奧治療公司
(Get Rating)
(獲取評級)
Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.
Xilio Treateutics，Inc.是一家臨牀階段的生物技術公司，開發免疫療法來改善癌症患者的免疫系統。其檢查點抑制計劃包括XTX101，這是一種臨牀分期、腫瘤選擇性的抗CTLA-4單抗，正處於實體瘤患者的1/2期臨牀試驗中。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Xilio Therapeutics (XLO)
- Oil Is a Compelling Reason The Sell-Off In Stocks Isn't Over
- Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
- Six Flags is a Ride You Don't Want to Get Stuck On
- Hanesbrands May be Signaling a Bad Week for Retail Stocks
- Vision Hydrogen, Now Vision Energy, Puts Hopes In Stock Split
- 免費獲取StockNews.com關於希利奧治療公司(XLO)的研究報告
- 油價是股市拋售尚未結束的一個令人信服的原因
- 中盤Neurocrine生物科學是井噴後的第三季度報告嗎？
- 六面旗幟是一種你不想被困住的旅程
- Hanesbrand可能發出零售類股本週表現不佳的信號
- 願景氫，現在的願景能源，將希望寄託在股票拆分上
Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《喜力治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Xilio Treeutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。